Faslodex

Selected form

There is no image.

Fulvestrant

Method of action: Antiestrogenic, Antitumour, Endocrine Therapy

Treatment option: Metastatic Breast Cancer, Cancer, Breast Cancer, Breast Cancer In Women

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Faslodex

Faslodex is a prescription-only pharmacological preparation whose active ingredient is Fulvestrant, a synthetic organic compound used in hormone therapy. This medication is clinically recognized as an antineoplastics agent, specifically designed to interfere with hormone-driven cellular processes.

Property	Description
Active ingredient	Fulvestrant
Form	Solution for injection (prefilled syringe)
Pharmacological class	Selective Estrogen Receptor Degrader (SERD)
Common use	Anti-estrogen therapy for hormone-sensitive conditions
Origin	Synthetic organic molecule

What is Faslodex (Fulvestrant) and Its Pharmaceutical Identity?

Faslodex is a specialized preparation of Fulvestrant delivered as a solution for injection intended for deep intramuscular administration. The active substance is provided in the unique dosage form of a prefilled syringe, which contains the drug formulated in an oil solution vehicle necessary for slow release. The high-level composition includes the active ingredient Fulvestrant dissolved in a base containing co-solvents like alcohol and a release rate modifier such as castor oil. This particular formulation and administration route are distinguishing features of Fulvestrant, supporting its sustained therapeutic effect.

Classification: Hormone Therapy and Selective Estrogen Receptor Degrader (SERD)

Fulvestrant is classified as a pure antiestrogen that functions as a Selective Estrogen Receptor Degrader (SERD), placing it within the general class of hormone therapy. Unlike older anti-estrogen agents, Fulvestrant acts as a complete Estrogen Receptor Antagonist—a key differentiating factor. This mechanism is unique because it ensures both the competitive binding and the subsequent physical degradation of the estrogen receptor protein itself. This dual action involves high binding affinity and the ability to effectively remove the receptor.

What is the General Purpose of Antiestrogenic Therapy?

The general purpose of this therapy is to create a complete anti-estrogen environment by actively disrupting the estrogen-dependent growth signal in target cells. Fulvestrant achieves this by promoting the rapid downregulation of estrogen receptors, thereby inhibiting estrogen signaling. This foundational action is essential for managing conditions where cell proliferation is reliant on the presence of estrogen, providing a targeted intervention against hormonal influence.

What side effects are possible with Faslodex?

Possible Side Effects and Safety Information

The safety profile of Fulvestrant, the active ingredient in Faslodex, is formally organized in regulatory documents by the frequency and type of documented adverse reactions.

Classification	Examples of Reactions (System-Organ Class)
Very Common (Affecting ge 1 in 10 patients)	General: Injection site reactions, Asthenia (weakness), Fatigue, Hot flashes. Gastrointestinal: Nausea, Vomiting. Hepatobiliary: Increased hepatic enzymes (ALT, AST, ALP). Musculoskeletal: Bone pain, Arthralgia (joint pain), Back pain.
Common (Affecting ge 1 in 100 to < 1 in 10)	Infections: Urinary tract infections. Nervous: Headache, Peripheral neuropathy, Sciatica, Neuralgia. Gastrointestinal: Constipation, Diarrhoea, Anorexia (loss of appetite). Other: Thrombocytopenia (low platelet count), Rash, Alopecia.
Uncommon (Affecting ge 1 in 1,000 to < 1 in 100)	Hypersensitivity reactions (e.g., angioedema, urticaria), Hepatic failure, Hepatitis, Injection site haemorrhage/haematoma.

Serious Safety Considerations and Constraints

Official regulatory labeling highlights specific safety considerations and physiological constraints:

Injection Site-Related Nerve Damage is a recognized risk due to the proximity of the sciatic nerve during deep intramuscular administration, with reported events including sciatica, neuralgia, and peripheral neuropathy.
Hepatic Impairment: The medication is contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Increased exposure occurs in moderate hepatic impairment.
Embryo-Fetal Toxicity: Based on its mechanism, the drug can cause fetal harm. Women of reproductive potential must use effective contraception during treatment and for a period after the last dose.
Risk of Bleeding: Caution is advised in patients with bleeding diatheses, thrombocytopenia, or those receiving anticoagulant treatment due to the potential for injection site bleeding.
Assay Interference: Fulvestrant can interfere with antibody-based serum estradiol assays, potentially resulting in falsely elevated estradiol measurements.

Overdose and Emergency Response

Overdose scope

Feature	Official Regulatory Statement
Documented overdose presentations	Isolated reports of overdose with Faslodex have been noted in human data, but official regulatory labeling does not define a specific clinical symptom profile or associated laboratory abnormalities.
Physiological systems affected (as stated in label)	Regulatory documents do not identify specific human physiological systems primarily affected by an overdose. Animal data suggests that effects from high doses would be limited to phenomena related to the drug's anti-estrogenic activity.
Dose-related or exposure-related factors (if applicable)	No specific toxic dose level or exposure factor is documented in the official regulatory sections.
Population-specific overdose notes (if applicable)	No specific management considerations or increased risks for any population subgroup (e.g., pediatric, geriatric) are documented within the overdose sections of the official labels.
Emergency-response statements (as written in official documents)	Symptomatic and supportive treatment is the formally recommended management approach.
When immediate medical help is required (label-derived phrasing only)	Urgent medical attention must be sought immediately if an overdose is suspected.

Overdose classifications (high-level)

Classification Type	Official Regulatory Statement
Severity classification (as defined in official documents)	The official regulatory documents do not define a formal classification of overdose severity.
Regulatory basis (EMA / FDA / etc.)	Information is grounded in the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents)	The official management guidance is constrained to the provision of symptomatic supportive treatment.

Resulting overdose structure

Official overdose statements:

If an overdose is suspected, urgent medical attention must be sought immediately.
Symptomatic and supportive treatment is the formally recommended management approach.
Regulatory information does not describe or specify a known antidote for Faslodex overdose.

Connection to the overall overdose profile (2–4 sentences): The regulatory overdose profile for Faslodex is primarily defined by the need for immediate medical response when an overdose is suspected. Since official documents state the lack of a known antidote and do not define a specific clinical symptom profile from human overdose, the entire management strategy mandated by regulators focuses on providing necessary symptomatic supportive care for any manifestations that may arise.

Therapeutic Uses of Faslodex

What Faslodex Treats: Main Uses and Benefits

This medication is commonly used for managing hormone receptor-positive (HR+) breast cancer that is locally advanced or has become metastatic. It is considered relevant for use in postmenopausal women with this condition, either as an initial endocrine therapy or following disease progression on previous anti-estrogen treatments.

Faslodex is commonly applied when symptoms escalate temporarily following previous hormonal treatments. It is considered relevant in clinical settings when supportive symptom management is appropriate to address disease activity. This provides supportive relief when symptoms interfere with routine activities and may assist with maintaining functional stability during symptomatic phases.

In modern care, the drug is commonly used across conditions presenting with acute episodes in combination therapy with other targeted agents. This approach generally assists with maintaining functional stability, and supports general well-being during symptomatic phases.

The overall purpose is for the medication to help address symptom clusters that may become intense or disruptive by addressing the estrogen-driven disease. This helps maintain a sense of stability when symptoms are more noticeable, and is relevant in contexts involving heightened systemic burden.

Quick Fact: Relief for Estrogen-Driven Disease Faslodex is applied in contexts where additional symptomatic support is needed to address the systemic symptom burden caused by estrogen-sensitive malignant cell proliferation.

Regulatory References

European Medicines Agency (EMA) Overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Faslodex (fulvestrant) is typically used for adult women, but eligibility is strictly governed by authoritative regulatory documentation based on absolute prohibitions and special population restrictions.

Contraindicated (Must Not Use)	Special Caution / Restricted Use
Known Hypersensitivity to fulvestrant or its components.	Moderate Hepatic Impairment (Child-Pugh B) requires a dose reduction.
Pregnancy or Lactation (Breastfeeding).	Severe Renal Impairment ( CrCl <30 ml/min), as safety is not established.
Severe Hepatic Impairment (Child-Pugh C).	Patients with bleeding diatheses, thrombocytopenia, or those taking anticoagulants (due to the intramuscular injection risk).

Use in the pediatric population (children and adolescents) is not recommended, as official regulatory data on safety and efficacy in this age group have not been established. Women of childbearing potential must be advised to use effective contraception during and for a specified time after treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Faslodex (Fulvestrant) establishes a limited profile for clinically significant drug-drug interactions. Regulatory bodies have documented that there are no known drug-drug interactions that necessitate a dose adjustment for Faslodex. This conclusion is based on clinical studies demonstrating that co-administration with strong inhibitors (e.g., ketoconazole) or strong inducers (e.g., rifampin) of the CYP3A4 enzyme did not alter fulvestrant pharmacokinetics.

Interaction Type	Official Regulatory Statement
Drug-Drug	No clinically relevant interactions documented with CYP3A4 agents.
Procedural/Physical	Use with caution in patients with bleeding diatheses, thrombocytopenia, or those taking anticoagulants due to the risk of hematoma at the intramuscular injection site.
Population-Specific	Increased systemic exposure (AUC) is documented in patients with moderate hepatic impairment (Child-Pugh Class B). Use in severe hepatic impairment is contraindicated.
Diagnostic Interference	May interfere with estradiol measurement by immunoassay, causing falsely elevated serum levels.

This structure shows that the product's constraints are defined by its administration route and specific patient metabolism, rather than conventional metabolic drug-drug interactions. No mandatory timing separation rules are required for co-administered medicines.

Mechanism of Action

Competitive Blockade of the Estrogen Receptor

This domain covers the drug’s primary molecular action: binding to the Estrogen Receptor (ER) in target cells. The active ingredient, Fulvestrant, acts as a pure antagonist by competitively occupying the receptor’s binding site. This immediate interaction prevents the body's natural estrogen from initiating a response, which acts to suppress the estrogen-signaling pathway.

Selective Receptor Degradation (SERD)

The mechanism of Faslodex involves its classification as a Selective Estrogen Receptor Degrader (SERD). Binding causes an unstable change in the ER's structure, which tags the receptor protein for destruction by the ubiquitin-proteasome pathway. This rapid and physical downregulation of ER protein levels results in a suppression of signaling, leading to the inhibition of estrogen-mediated cellular proliferation.

Functional Constraints on the Mechanism

The mechanism is constrained by biological factors like activating ESR1 mutations, which can compromise the drug’s ability to fully eliminate the receptor’s function. Furthermore, the action is specific to the ER axis and does not modulate cell growth driven by parallel, non-hormonal pathways, defining the functional constraints on the physiological effect.

Dosage and Administration Information

How to use Faslodex (Fulvestrant) — Administration Guidelines

Faslodex is administered as an intramuscular (IM) injection by a healthcare professional. It is provided in pre-filled syringes as a clear, colorless to yellow, viscous solution and must be visually inspected for discoloration or particulate matter before use.

Dosing Schedule

The recommended standard dose is 500 mg of fulvestrant, administered at specific time points. The drug is intended for adults, including the elderly, and is independent of meals.

Administration Detail	Standard Rules (for 500 mg dose)
Route	Intramuscular (IM) injection into the gluteal area (buttock).
Dose Volume	Two separate 5-mL injections, one in each buttock, to deliver the 500 mg total dose.
Frequency	Days 1, 15, 29, and once per month (every 28 days) thereafter.
Hepatic Impairment	A dose of 250 mg is recommended for patients with moderate hepatic impairment (Child-Pugh Class B).

Administration Procedure

Each injection must be administered slowly, taking one to two minutes per injection. The healthcare provider must exercise caution when injecting at the dorsogluteal site due to the proximity of the sciatic nerve. If a dose is missed, it should be administered as soon as possible, and the regular monthly schedule should be resumed.

This medication follows a specific protocol that requires careful timing and slow injection technique into the muscle. The initial dosing period is front-loaded, with the second dose given after 14 days, followed by the regular monthly maintenance schedule every 28 days for continuous treatment.

Recent Clinical Evidence

Faslodex: Recent Clinical Evidence

Evidence for First-Line Use in HR+, HER2- Advanced Breast Cancer (Monotherapy)

Research has evaluated Faslodex for initial endocrine treatment in postmenopausal women whose hormone receptor-positive, HER2-negative advanced breast cancer was not previously treated with endocrine therapy in the advanced setting. Large, high-quality studies explored this comparison by randomly assigning patients to receive either Faslodex or the active comparator studied, like anastrozole.

These studies monitored patient outcomes related to tumor response and Progression-Free Survival (PFS), which is an outcome related to disease activity. Findings describe patterns observed in the studies where, for certain groups of patients, Faslodex was associated with a difference in these measured timeframes compared to the active comparator studied. What remains uncertain is the full characterization of long-term effects beyond the typical follow-up periods of the trials.

Combination Study Evidence (with CDK4/6 and PIK3CA Inhibitors)

Clinical research examined Faslodex in combination with two different types of targeted drugs: CDK4/6 inhibitors and PIK3CA inhibitors. These studies were evaluated in patients whose disease was observed in a variety of treatment settings. The trials compared the combination against Faslodex plus a placebo and monitored outcomes like Progression-Free Survival and Overall Survival (OS), an outcome related to long-term study of patients.

For the combination with CDK4/6 inhibitors, data show patterns related to different PFS measurements for the combination regimen compared to Faslodex alone. For the PIK3CA inhibitor combination, the research explored outcomes only in patients whose tumors carried a specific PIK3CA gene mutation. Results apply only to the populations studied, providing limited information for long-term outcomes in patients without that specific mutation.

What is Still Uncertain About the Research for Faslodex

The research continues to evolve, and several areas still require further investigation. Evidence quality varies across studies, especially between earlier Phase II trials and later Phase III trials. Findings were mixed or data are still emerging regarding the order of Faslodex use after a patient has progressed on a CDK4/6 inhibitor combination. Overall, research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

Fulvestrant 500 mg versus anastrozole for the first-line treatment of advanced breast cancer: a meta-analysis of the FIRST and FALCON trials

Frequently Asked Questions (FAQ)

Common questions about Faslodex (FAQ)

Q: Is Faslodex a type of chemotherapy?

A: Faslodex is not classified as a traditional chemotherapy drug. It is a type of hormone therapy classified as a Selective Estrogen Receptor Degrader (SERD). This classification relates to its mechanism of action, which involves blocking and causing the degradation of estrogen receptors.

Q: How is Faslodex different from an aromatase inhibitor?

A: The drug is classified as a Selective Estrogen Receptor Degrader (SERD). This function involves binding to and causing the destruction of the estrogen receptor protein.

Q: What kind of cancer is Faslodex used for?

A: Official labeling describes Faslodex as indicated for the treatment of hormone receptor-positive advanced or metastatic breast cancer.

Q: Can Faslodex be used for men?

A: Official patient information indicates that the drug is intended for adult women and is not recommended for use in men or children.

Q: Does Faslodex cause weight gain or loss?

A: Official side effect data lists decreased appetite and weight loss as possible reactions to the drug. Weight gain is not commonly listed in the safety profile.

Q: Will Faslodex change my mood or cause depression?

A: Official product information states that depression and anxiety are listed as common side effects of Faslodex. Other less common mood or mental changes have also been reported.

Q: How long does it take for Faslodex to start working?

A: Faslodex is formulated to be absorbed slowly after the deep intramuscular injection. Pharmacokinetic studies describe that the maximum concentration of the drug is usually reached around five days after administration.

Q: How long can a person stay on Faslodex treatment?

A: Faslodex is administered on a set monthly schedule. The total duration of therapy is not a fixed length and is managed until there is evidence of disease progression or unacceptable toxicity, as described in clinical practice.

Q: What should I avoid eating or drinking while on Faslodex?

A: No specific special diet, foods, or drinks are required or prohibited in the official prescribing information for Faslodex monotherapy.

Q: Are there any common over-the-counter medicines that interact with Faslodex?

A: Regulatory documents state that Faslodex has no known drug-drug interactions that require a dosage adjustment. Official information notes that caution is advised in patients receiving anticoagulant treatment due to the risk of bleeding or hematoma at the injection site.

Q: Can you take pain relievers like ibuprofen while on Faslodex?

A: Regulatory documents state that Faslodex has no known drug-drug interactions that require a dosage adjustment. Official information notes that caution is advised in patients receiving anticoagulant treatment due to the risk of bleeding or hematoma at the injection site.

Q: Is Faslodex used for all stages of breast cancer?

A: Official indications specify that Faslodex is used for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive. It is not indicated for the early stages of breast cancer.

Q: Does Faslodex affect fertility?

A: Based on animal studies, official documents indicate that the drug may temporarily impair fertility in both females and males of reproductive potential.

Q: Are there any long-term side effects associated with Faslodex use?

A: The drug's safety profile documents all known adverse reactions by frequency. Official clinical evidence notes that the full characterization of effects beyond the typical follow-up periods of the clinical trials remains uncertain.

Q: What should I do if the injection site is sore?

A: Injection site reactions, including pain or inflammation, are listed as a very common side effect. Official patient safety information includes advice that nerve-related pain (such as numbness or tingling) or soreness that is severe or continues should be reported to a healthcare professional.

Q: Does alcohol interact with Faslodex?

A: The official prescribing information does not list a specific interaction between oral alcohol consumption and Faslodex. Use of alcohol is a topic to be reviewed with a healthcare professional.

Q: Is Faslodex a targeted therapy?

A: Faslodex acts as a Selective Estrogen Receptor Degrader (SERD) and an Estrogen Receptor antagonist. It is a targeted intervention that specifically acts on the estrogen receptor to suppress hormone signaling.

Q: What is the half-life of Faslodex?

A: Pharmacokinetic data from the official product information indicates that the elimination half-life of the drug after intramuscular injection is approximately 40 to 50 days.

Q: Can Faslodex be given at home?

A: Regulatory guidance requires that the injection be administered slowly by a healthcare professional using a specific technique. This is required due to the depth of the intramuscular injection and the proximity of the sciatic nerve.

Q: What are the signs of a serious side effect from Faslodex?

A: Official patient safety information highlights specific serious effects. These include signs of a severe allergic reaction, signs of bleeding, and nerve-related symptoms, which should be reported to a professional.

Q: Why do official documents mention 'tamoxifen failure' when discussing Faslodex use?

A: The official indication notes the drug is used after disease progression following prior antiestrogen therapy. This may include previous treatments such as Tamoxifen.

Q: Where can I find official patient information about Faslodex?

A: Official patient information is typically made available on the websites of the drug's manufacturer or by governmental health authorities, such as the FDA, EMA, or Health Canada.

Q: Is there a generic version of Faslodex available?

A: Yes, regulatory records confirm that generic versions of fulvestrant, which is the active ingredient in Faslodex, have been approved.

Q: Is Faslodex only used after menopause?

A: Faslodex monotherapy is indicated for use in postmenopausal women. Its use in premenopausal or perimenopausal women is generally restricted to specific combination regimens that require co-administration of an LHRH agonist.

How should Faslodex be stored and disposed of?

How to Store and Dispose of Faslodex

Faslodex (fulvestrant) injection requires refrigerated storage to maintain its stability. The medication must be kept between 2 C and 8 C (36 F and 46 F) and must not be frozen. The product should remain in its original outer carton until use to ensure it is protected from light. To reduce administration discomfort, the single-use syringe may be allowed to reach room temperature for up to one hour prior to injection.

As a hazardous drug, Faslodex must be kept out of the sight and reach of children. Used syringes and needles must be immediately placed in a designated sharps disposal container. Unused or expired medication must be disposed of according to local regulatory requirements and should not be discarded into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.